Quick Answer
RIGEL PHARMACEUTICALS INC reported Operating Income of $125.47 million for fiscal year 2025.
RIGEL PHARMACEUTICALS INC Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $125.47M | +418.6% |
| 2024 | $24.19M | +218.1% |
| 2023 | -$20.49M | +63.1% |
| 2022 | -$55.55M | -344.5% |
| 2021 | -$12.50M | +56.9% |
| 2020 | -$28.97M | +58.1% |
| 2019 | -$69.09M | +4.9% |
| 2018 | -$72.68M | +8.7% |
| 2017 | -$79.62M | -14.2% |
| 2016 | -$69.74M | -34.8% |
| 2015 | -$51.74M | +43.3% |
| 2014 | -$91.25M | -2.0% |
| 2013 | -$89.47M | +10.0% |
| 2012 | -$99.38M | -15.1% |
| 2011 | -$86.37M | -344.6% |
| 2010 | $35.32M | +131.5% |
| 2009 | -$112.04M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $28.42M | +102.2% | -53.5% |
| June 30, 2025 | $61.10M | +13569.6% | +378.4% |
| March 31, 2025 | $12.77M | +283.4% | -9.1% |
| September 30, 2024 | $14.06M | +414.8% | +3044.5% |
| June 30, 2024 | $447.0K | +108.5% | +106.4% |
| March 31, 2024 | -$6.97M | +45.3% | -56.0% |
| September 30, 2023 | -$4.46M | +75.7% | +15.2% |
| June 30, 2023 | -$5.27M | +59.4% | +58.6% |
- RIGEL PHARMACEUTICALS INC showed an increase of +418.6% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, RIGEL PHARMACEUTICALS INC’s operating income has grown by 212.0% (from -$112.04 million to $125.47 million).
- The most recent figure is from RIGEL PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: